VEGF-mediated angiogenesis of human pheochromocytomas is associated to malignancy and inhibited by anti-VEGF antibodies in experimental tumors

Surgery

Volumn 132, Issue 6, 2002, Pages 1056-1063

  Zielke, Andreas ^a,b,c   Middeke, Martin ^a,b,c   Hoffmann, Sebastian ^a,b,c   Colombo Benkmann, Mario ^a,b,c   Barth, Peter ^a,b,c   Hassan, Iyad ^a,b,c   Wunderlich, Annette ^a,b,c   Hofbauer, Lorenz C ^a,b,c   Duh, Quan Yang ^a,b,c   Hamberger, Bertil ^d   Nwariaku, Fiemu ^d   Frilling, Andrea ^d   Carter, W Bradford ^d   Mitchell, Bradford ^d   Pasieka, Janice L ^d  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD31 ANTIGEN; CD34 ANTIGEN; MESSENGER RNA; VASCULOTROPIN; VASCULOTROPIN ANTIBODY;

ADRENAL MEDULLA TUMOR; ANGIOGENESIS; ANIMAL CELL; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL NEOPLASM; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MICROVASCULATURE; NONHUMAN; NORTHERN BLOTTING; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TUMOR BLOOD FLOW; UMBILICAL VEIN;

EID: 0036915371     PISSN: 00396060     EISSN: None     Source Type: Journal    
DOI: 10.1067/msy.2002.128613     Document Type: Article

References (25)

1. Liu Q Djuricin G, Staren ED, Gattuso P, Gould VE, Shen J, et al. Tumor angiogenesis in pheochromocytomas and paragangliomas. Surgery 1996;120:938-42; discussion 942-3
2. Ferrara N. VEGF: Molecular and biological aspects. In: Cleasson-Welsh L, editor. Vascular Growth Factors and Angio-genesis. Heidelberg, Germany: Springer; 1999. p. 1-21.
3. Claffey KP, Wilkison WO, Spiegelman BM. Vascular endothelial growth factor: Regulation by cell differentiation and activated second messenger pathways. J Biol Chem 1992;267:16317-22.
4. Sheehy AM, Phung Y, Riemer RK, Black SM. Growth factor induction of nitric oxide synthase in rat pheochromocytoma cells. Brain Res Mol Brain Res 1997; 52:71-7.
5. Olah ME, Roudabush FL. 2000 Down-regulation of vascular endothelial growth factor expression after A(2A) adenosine receptor activation in PC12 pheochromocytoma cells. J Pharmacol Exp Ther 1997;293:779-87.
6. Zielke A, Wong MG, Siperstein AE, Clark OH, Rothmund M, Duh QY. Antiproliferative effect of suramin on primary, cultures of human pheochromocytomas and rat PC12 pheochromocytoma cells. J Surg Oncol 1997;66:11-8.
7. Zielke A, Bresalier RS, Siperstein AE, Clark OH, Rothmund M, Duh QY. A unique allogenic model of metastatic pheochromocytoma: PC12 rat pheochromocytoma xenografts to nude mice and establishment of metastases-derived PC12 variants. Clin Exp Metastasis 1998;16:341-52.
8. Hofbauer LC, Gori F, Riggs BL, Lacey DL, Dunstan CR, Spelsberg TC, et al. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: Potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 1999;140:4382-9.
9. Gess B, Sander P, Kurtz A. Differential effects of kinase inhibitors on erythropoietin and vascular endothelial growth factor gene expression in rat hepatocytes. Eur J Physiol 1996;432:426-32.
10. Hata Y, Nakagawa K, Ishibashi T, Inomata H, Ueno H, Sueishi K. Hypoxia induced expression of vascular endothelial growth factor by retinal glial cells promotes in vitro angiogenesis. Virchows Arch 1995;426:479-86.
11. Sato K, Miyakawa M, Onoda N, Demura H, Yamashita T, Miura M, et al. Increased concentration of vascular endothelial growth factor/vascular permeability factor in cyst fluid of enlarging and recurrent thyroid nodules. J Clin Endocrinol Metab 1997;82:1968-73.
12. Passaniti A, Taylor RM, Pili R, Guo Y, Long PV, Haney JA, et al. A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. Lab Invest 1992;67:519-28.
13. Senger DR, Claffey KP, Benes JE, Perruzzi CA, Sergiou AP, Detmar M. Angiogenesis promoted by vascular endothelial growth factor: Regulation through alpha1beta1 and alpha2beta1 integrins. Proc Natl Acad Sci U S A 1997;94:13612-7.
14. Berman ME, Xie Y, Muller WA. Roles of platelet/endothelial cell adhesion molecule-1 (PECAM-1, CD31) in natural killer cell trans-endothelial migration and beta 2 integrin activation. J Immunol 1996;156:1515-24.
15. Barth PJ, Weingärtner K, Köhler HH, Bittinger A. Assessment of the vascularization in prostatic carcinoma: A morphometric investigation. Hum Pathol 1996;27:1306-10.
16. Folkman J, Hochberg M. Self regulation of growth in three dimensions. J Exp Med 1973;138:745-53.
17. Gasparini G, Toi M, Gion M, Verderio P, Dittadi R, Hanatani M, et al. Prognostic significance of VEGF protein in node negative breast carcinoma. J Natl Cancer Inst 1997;89:139-47.
18. Maeda K, Chung YS, Ogawa Y, Takatsuka S, Kang SM, Ogawa M, et al. Prognostic value of VEGF expression in gastric carcinoma. Cancer 1996;77:858-63.
19. Toi M, Kondo S, Suzuki H, Yamamoto Y, Inada K, Imazawa T, et al. Quantitative analysis of VEGF in primary breast cancer. Cancer 1996;77:1101-6.
20. Kolomecki K, Stepien H, Bartos M, Kuzdak K. Usefulness of VEGF, MMP-2. MMP-3 and TIMP serum level evaluation in patients with adrenal tumors. Endocr Regul 2001;35:9-16.
21. Ohji H, Sasagawa I, Iciyanagi O, Suzuki Y, Nakada T. Tumorangiogenesis and Ki-67 expression in pheochromocytoma. BJU Int 2001;87:381-5.
22. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, et al. Inhibition of VEGF induced angiogenesis suppresses tumor growth in vivo. Nature 1993;362:841-4.
23. Asano M, Yukita A, Matsumoto T, Kondo S, Suzuki H. Inhibition of tumor growth and metastasis by an immunoneutralizing monoconal antibody to human vascular endothelial growth factor/vascular permeability factor 121. Cancer Res 1995;55:5296-301.
24. Kanai T, Konno H, Tanaka T, Baba M, Matsumoto K, Nakamura S, et al. Anti-tumor and anti-metastatic effects of human-vascular-endothelial-growth-factor-neutralizing anti-body on human colon and gastric carcinoma xenowansplanted orthotopically into nude mice. Int J Cancer 1998;77:933-6.
25. Melnyk O, Zimmerman M, Kim KJ, Schuman M. Neutralizing anti-vascular endothelial growth factor antibody inhibits further growth of established prostate cancer and metastases in a pre-clinical model. J Urol 1999;161:960-3.